Abstract
ClinicalTrials.gov: NCT02521441. This Phase II trial evaluates efbemalenograstim alfa, a non-PEGylated Fc-fusion protein, as a long-acting alternative to daily filgrastim for preventing chemotherapy-induced neutropenia (CIN).
Introduction
Myelosuppressive chemotherapy frequently causes neutropenia, a significant reduction in absolute neutrophil counts (ANC) that increases infection risk. While Granulocyte Colony-Stimulating Factors (G-CSFs) like filgrastim are standard treatments, short-acting versions require daily injections for up to two weeks. Existing long-acting versions typically use PEGylation (adding polyethylene glycol) to extend half-life, which can trigger anti-PEG antibody responses that reduce efficacy or cause allergic reactions. Efbemalenograstim alfa (F-627) addresses this by using an Fc-fusion design to extend half-life without PEGylation.
Methods
This multicenter, randomized, open-label Phase II trial enrolled 138 female breast cancer patients receiving epirubicin and cyclophosphamide (EC) chemotherapy. Patients were randomized into three groups: efbemalenograstim alfa at 10 mg or 20 mg (single injection per cycle), or daily filgrastim (5 μg/kg/day).
The study drug is a G-CSF-Fc fusion protein that utilizes the natural neonatal Fc receptor (FcRn) recycling pathway to achieve a half-life of approximately three weeks, aligning with standard chemotherapy cycles. Analysis was performed on Intent-to-Treat (ITT), Per-Protocol (PP), and Safety sets.
Results
Both doses of efbemalenograstim alfa demonstrated non-inferiority to filgrastim. In Cycle 1, the 20 mg dose group had a mean duration of moderate/severe neutropenia of 0.6 days, compared to 0.8 days for the filgrastim group.
As shown in Figure 3, the 20 mg dose group maintained a higher median ANC nadir ($2.2 \times 10^9/L$) than the filgrastim group ($1.4 \times 10^9/L$), suggesting superior protection during the cycle's lowest point. Furthermore, the 20 mg group exhibited faster ANC recovery post-nadir (0.8 days vs. 1.2 days). Safety profiles were favorable, with lower drug-related adverse events in the 20 mg group (10.0%) compared to filgrastim (31.7%), and no development of neutralizing antibodies.
Discussion and Conclusion
Efbemalenograstim alfa offers a promising "non-PEG" advantage, potentially avoiding issues related to anti-PEG antibodies while providing the convenience of a single injection. The dimeric structure of the fusion protein may also enhance G-CSF receptor activation compared to monomeric forms. While this Phase II study is limited by its sample size and focus on a specific cancer type, the results support the 20 mg dose for further Phase III investigation. This novel Fc-fusion protein represents a significant step toward more effective and patient-friendly management of chemotherapy-induced neutropenia.
Summary updated